Chemed (NYSE:CHE) Rating Lowered to “Strong Sell” at Zacks Research

Chemed (NYSE:CHE) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Wednesday,Zacks.com reports.

A number of other research analysts have also recently weighed in on CHE. Royal Bank Of Canada reissued a “sector perform” rating and set a $422.00 price objective (down from $572.00) on shares of Chemed in a research note on Friday, February 27th. Jefferies Financial Group downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Thursday, January 22nd. Oppenheimer cut their price target on Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Chemed presently has a consensus rating of “Hold” and an average target price of $498.00.

Chemed Stock Up 0.3%

Shares of CHE stock opened at $412.36 on Wednesday. The stock has a market cap of $5.68 billion, a P/E ratio of 22.45, a P/E/G ratio of 1.63 and a beta of 0.46. Chemed has a fifty-two week low of $385.00 and a fifty-two week high of $623.60. The business has a fifty day simple moving average of $444.70 and a 200-day simple moving average of $443.11.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $6.42 EPS for the quarter, missing analysts’ consensus estimates of $7.02 by ($0.60). The business had revenue of $639.34 million during the quarter, compared to analyst estimates of $659.09 million. Chemed had a net margin of 10.48% and a return on equity of 25.66%. Chemed’s revenue was down .1% on a year-over-year basis. During the same period in the previous year, the company posted $6.83 earnings per share. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. On average, sell-side analysts anticipate that Chemed will post 21.43 earnings per share for the current year.

Hedge Funds Weigh In On Chemed

Several institutional investors have recently added to or reduced their stakes in CHE. Monetary Solutions Ltd acquired a new stake in Chemed in the 4th quarter worth about $25,000. Los Angeles Capital Management LLC acquired a new stake in shares of Chemed in the fourth quarter worth approximately $26,000. Smartleaf Asset Management LLC boosted its position in shares of Chemed by 71.4% in the third quarter. Smartleaf Asset Management LLC now owns 60 shares of the company’s stock worth $27,000 after acquiring an additional 25 shares during the last quarter. BOK Financial Private Wealth Inc. purchased a new stake in Chemed in the fourth quarter valued at approximately $27,000. Finally, First Horizon Corp acquired a new position in Chemed during the third quarter worth approximately $31,000. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.